Sun Nuclear Opens QADS 2026 in Rome, Highlighting Innovations in Clinical QA and Patient Safety
Sun Nuclear, a Mirion Medical company, officially launched the 15th annual QA & Dosimetry Symposium (QADS) in Rome, Italy, today, bringing together a global community of clinical physicists and radiation medicine professionals. The two-day event, which continues through the next day, gathers more than 230 participants representing nearly 40 countries, fostering an environment where experts can share practical insights, discuss emerging approaches, and exchange real-world experiences that are shaping the future of quality assurance (QA) and patient safety in cancer care.
QADS has long been recognized as a peer-driven forum that emphasizes practical, clinically relevant applications. In 2026, the symposium builds on this legacy, offering sessions designed to address the evolving demands of modern radiation oncology, while maintaining a strong focus on improving workflow efficiency, data integration, and patient safety. Attendees have the opportunity to earn continuing education credits while engaging in technical discussions that bridge research, clinical practice, and technology innovation.
The symposium features a diverse range of presentations delivered by 24 distinguished speakers from around the world. Topics span the full spectrum of clinical QA, including future directions in machine and patient QA, in‑vivo dosimetry, stereotactic radiosurgery (SRS), and stereotactic body radiation therapy (SBRT) quality assurance. Sessions also cover safety and guideline-driven tool selection, along with the latest emerging technologies in the field, such as theranostics, artificial intelligence (AI), and automation. By addressing these topics, QADS 2026 offers attendees a holistic perspective on both current best practices and the transformative possibilities emerging within radiation medicine.
A central highlight of QADS 2026 is the introduction of Sun Nuclear’s latest innovation in daily machine QA, Daily QA™ 4 Pro. This new solution represents a significant advancement in the integration of dosimetry and imaging/positioning checks into a single indexed, imageable device. The Daily QA 4 Pro is designed to streamline workflow by enabling faster setup, reducing the need for multiple room entries, and improving consistency in daily QA routines. By consolidating critical QA functions into a single device, it allows clinical teams to better monitor and maintain machine performance, ultimately contributing to enhanced patient safety and treatment quality.
Dr. David Barbee, Ph.D., DABR, from NYU Langone Health, will deliver the keynote presentation at QADS 2026. Dr. Barbee’s session focuses on the early clinical experience with the Daily QA 4 Pro, highlighting how the device performs in real-world clinical settings. By examining comparative measurement data from independent QA tools and machine performance checks, his presentation emphasizes how diverse data sources can be synthesized, interpreted, and meaningfully applied within clinical QA workflows. Attendees will gain insights into the efficiencies, limitations, and opportunities associated with modern QA practices, particularly as clinics strive to improve data visibility, trend analysis, and workflow understanding. This keynote sets the stage for a broader discussion on the future trajectory of machine QA and the integration of emerging technologies in routine clinical practice.
Beyond the Daily QA 4 Pro, QADS 2026 will also showcase Plan AI™, an AI-powered solution designed to accelerate radiation therapy planning while simultaneously improving plan quality and consistency. Recently awarded the CE mark, Plan AI is now available for sale in Europe. The symposium offers attendees hands-on demonstrations of Plan AI, providing practical exposure to the capabilities of AI-driven plan quality enablement. These demonstrations complement the technical sessions by giving participants an opportunity to see firsthand how AI can streamline workflows, support clinical decision-making, and enhance patient outcomes.
Luis Rivera, Executive Vice President for Mirion Medical and President of Sun Nuclear, emphasized the importance of forums like QADS in advancing clinical quality management. “As clinical quality management demands continue to grow, forums like QADS play a critical role in bringing the community together to share experiences, evaluate new approaches, and focus on what delivers real value in practice,” Rivera said. “QADS reflects our commitment to supporting physicists and clinical care teams with solutions and conversations that are grounded in clinical reality and focused on improving quality and efficiency.”
The symposium also serves as a platform for knowledge exchange between professionals working in diverse clinical environments, ranging from large academic medical centers to smaller community hospitals. This variety ensures that discussions address both high-end technological innovations and practical considerations that impact day-to-day clinical operations. By fostering dialogue across different healthcare settings, QADS encourages the adoption of best practices, promotes collaboration, and inspires innovation tailored to real-world challenges.
The event’s sessions are carefully curated to address multiple aspects of QA and patient safety. Topics such as in-vivo dosimetry and stereotactic radiation therapies reflect the growing complexity of treatment techniques, which demand high precision and stringent quality control measures. Meanwhile, sessions on guideline-driven tool selection and workflow optimization equip attendees with actionable strategies to enhance operational efficiency, reduce errors, and improve overall treatment quality. Emerging technologies, including AI and theranostics, offer participants a glimpse into the future of radiation medicine, highlighting how advanced tools can augment clinical decision-making and improve patient outcomes.
Mirion Medical, the parent company of Sun Nuclear, is a global leader in radiation safety, science, and medicine. The organization focuses on harnessing the transformative potential of ionizing radiation while providing innovative solutions that ensure safety and enhance quality across multiple end markets. Mirion’s Medical group, in particular, is dedicated to advancing cancer care by offering a comprehensive suite of solutions that support clinical teams in delivering safe, high-quality treatments. Headquartered in Atlanta, Georgia, Mirion employs approximately 3,200 people and maintains operations in 12 countries, underscoring its global reach and commitment to improving healthcare outcomes worldwide.
QADS 2026 exemplifies Mirion Medical’s commitment to fostering clinical innovation, knowledge sharing, and the continuous improvement of patient safety practices. Through the combination of technical presentations, keynote insights, and hands-on demonstrations of cutting-edge tools like Daily QA 4 Pro and Plan AI, the symposium provides participants with both the theoretical understanding and practical skills necessary to enhance quality assurance processes in radiation oncology.
